An In Vivo Functional Screen Uncovers miR-150-Mediated Regulation of Hematopoietic Injury Response  by Adams, Brian D. et al.
Cell Reports
ResourceAn In Vivo Functional Screen
Uncovers miR-150-Mediated Regulation
of Hematopoietic Injury Response
Brian D. Adams,1 Shangqin Guo,1 Haitao Bai,1,5 Yanwen Guo,1 Cynthia M. Megyola,1 Jijun Cheng,1 Kartoosh Heydari,2
Changchun Xiao,3 E. Premkumar Reddy,4 and Jun Lu1,*
1Department of Genetics, Yale Stem Cell Center, Yale Cancer Center and Yale Center for RNA Science and Medicine
2Department of Immunobiology, Yale Flow Cytometry Core Facility
Yale University, New Haven, CT 06520, USA
3Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
4Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
5Department of Hematology, Shanghai Jiaotong University Affiliated Shanghai First People’s Hospital, Shanghai 200080, China
*Correspondence: jun.lu@yale.edu
http://dx.doi.org/10.1016/j.celrep.2012.09.014SUMMARY
Hematopoietic stem and progenitor cells are often
undesired targets of chemotherapies, leading to
hematopoietic suppression requiring careful clinical
management. Whether microRNAs control hemato-
poietic injury response is largely unknown. We report
an in vivo gain-of-function screen and the identifica-
tion of miR-150 as an inhibitor of hematopoietic
recovery upon 5-fluorouracil-induced injury. Utilizing
a bone marrow transplant model with a barcoded
microRNA library, we screened for barcode abun-
dance in peripheral blood of recipient mice before
and after 5-fluorouracil treatment. Overexpression
of screen-candidate miR-150 resulted in significantly
slowed recovery rates across major blood lineages,
with associated impairment of bone marrow clono-
genic potential. Conversely, platelets and myeloid
cells frommiR-150 null marrow recovered faster after
5-fluorouracil treatment. Heterozygous knockout of
c-myb, a conserved target of miR-150, partially
phenocopied miR-150-forced expression. Our data
highlight the role of microRNAs in controlling hema-
topoietic injury response and demonstrate the power
of in vivo functional screens for studying microRNAs
in normal tissue physiology.INTRODUCTION
Tissue stem and progenitor cells, such as hematopoietic stem
and progenitor cells (HSPCs), are responsible for sustaining
tissue homeostasis and replenishing the loss of mature lineages
after tissue injury. A major cause of hematopoietic injury stems
from side effects associatedwith chemotherapy for solid tumors,
which often indiscriminately kill or impair the function of HSPCs,
leading to bone marrow toxicity with an acute reduction in1048 Cell Reports 2, 1048–1060, October 25, 2012 ª2012 The Authoperipheral blood cell counts (Wang et al., 2006). The affected
cell types include platelets and myeloid cells, which are respon-
sible for blood coagulation and controlling infection, respec-
tively. Such undesired side effects can lead to life-threatening
conditions in the weeks during and following administration of
chemotherapy and often limit therapeutic doses (Wang et al.,
2006; Lyman et al., 2003). Thus, understanding the molecular
mechanisms governing the recovery rate of circulating mature
blood cells remains an important question.
MicroRNA (miRNA)-mediated posttranscriptional control has
emerged as a critical regulatory mechanism in diverse biological
processes. These small noncoding RNAs target endogenous
messenger RNAs, largely through cognitive sites in the 30
untranslated regions (UTRs), resulting in target degradation or
translational inhibition (Bartel, 2009). Multiple laboratories,
including ours, have reported that specific miRNAs can control
hematopoiesis (Baltimore et al., 2008; Guo et al., 2010; Lu
et al., 2008; Garzon and Croce, 2008), yet it remains largely
unknown whether miRNAs can regulate hematopoietic recovery
rate after injury.
Functional screens can provide a direct and powerful
approach to identify gene functions in mammalian biology.
Indeed, in vitro screens based on miRNA expression libraries
have proven highly useful (Voorhoeve et al., 2006; Izumiya
et al., 2010; Huang et al., 2008; Poell et al., 2011). For instance,
miR-372/miR-373 were found to be potent oncogenes that have
a stronger effect than p53 knockdown in relieving oncogene-
induced senescence (Voorhoeve et al., 2006). Despite the
successes of in vitro miRNA screens, in vivo miRNA screens
have not been reported in mammals. Specifically, questions
regarding physiological processes, such as studying HSPCs,
are often difficult to model in vitro because hematopoietic stem
cells easily lose stemness outside the host environment. Thus,
genetic screens to study HSPCs were rarely attempted in vitro
or in vivo, often requiring large cohorts of mice (Ali et al., 2009;
Deneault et al., 2009; Hope et al., 2010; Wang et al., 2012).
Recent studies with barcoded shRNA libraries (Zender et al.,
2008; Bric et al., 2009; Meacham et al., 2009; Wang et al.,
2012) suggest the prospect of an in vivo barcodedmiRNA screenrs
to study HSPC physiology, with multiple miRNAs screened in
each individual mouse, and analysis of barcode abundance to
deconvolute the contribution of each miRNA. There are,
however, two limiting factors for a barcoded HSPC screen.
One is the limited number of HSPCs from in vivo sources, making
it challenging to obtain enough cell coverage for large numbers
of genetic constructs. Second, only a limited number of normal
HSPCs may engraft each lethally irradiated transplantation
recipient (Lu et al., 2011), creating a bottleneck for analyzing
a large number of genes per recipient mouse. In this regard,
miRNAs are especially favorable candidates for medium-sized
library screens because only a few hundred miRNAs are pre-
dicted to target >30% of the protein-coding transcriptome
(Bartel, 2009), thus allowing for a small number of miRNAs to
represent substantial gene regulatory perturbations.
In this study, we established an unbiased, in vivo, gain-of-
function screen to identify miRNAs involved inmodulating hema-
topoietic recovery in mice upon chemotherapeutic challenge.
The term ‘‘hematopoietic recovery’’ in this paper is used to
describe the recovery of peripheral blood cells after chemo-
therapy-induced suppression of peripheral blood parameters,
thus reflecting underlying mechanisms of both regeneration
and apoptosis of bone marrow progenitors. We modeled
chemotherapy response using 5-fluorouracil (5-FU), a clinically
used drug for solid cancers (Longley et al., 2003). With a library
of 135 hematopoietic-expressed miRNAs, we assayed the func-
tion of 35–71 miRNAs in each recipient mouse. Three out of four
screen candidates were validated to inhibit hematopoietic
recovery. Among them, gain- and loss-of-function experiments
established the importance of miR-150, partially through target-
ing c-myb, a conserved miR-150 target. Our data highlight the
role of miRNAs in controlling response of HSPCs toward tissue
injury and demonstrate the feasibility and power of functional
in vivo barcode screens for studying tissue physiology.
RESULTS
Injury from 5-FU Induces Vast miRNA Expression
Changes in the Bone Marrow
To identify miRNAs that regulate hematopoietic response after
5-FU-induced injury, we initially analyzed miRNA expression
changes in bone marrow cells from mice with or without 5-FU
treatment. Global miRNA expression profiling of the 5-FU and
untreated cohorts showed that 92 miRNAs (among 168 that
passed the detection threshold) were significantly upregulated
or downregulated, with false discovery rates <5% (Figure S1A;
Table S1). This large number of altered miRNAs made it difficult
to identify which miRNAs serve as functional regulators of hema-
topoietic injury response. We thus went on to perform an in vivo
functional screen.
Developing a miRNA Expression Library and
Bead-Based Barcode Detection System
As a first step toward establishing a physiologically relevant
in vivo gain-of-function screen, we constructed an expression
library comprised of individual miRNAs that are expressed in
the hematopoietic system (Figure S1B). These miRNAs (Table
S2) were chosen from publicly available deep-sequencing dataCellof hematopoietic tissues (Landgraf et al., 2007), largely based
on their abundance. In anticipation of limited numbers of HSPCs
that may engraft in eachmouse (Lu et al., 2011), we restricted the
size of the library to 135 miRNAs. For those miRNAs that can be
produced from multiple loci in the genome, only a single repre-
sentative locus was picked. With these design principles, we
PCR amplified genomic regions harboring the miRNA hairpins
and flanking sequences and individually cloned them into a
pMSCV-based retroviral vector, which is widely used to support
overexpression in the hematopoietic system (Lu et al., 2008; Guo
et al., 2010).
With a miRNA expression library in hand, we then developed
an inexpensive bead-based system that can readout the contri-
bution of each library construct among a pool of library-trans-
duced cells (Figure S1C). We took advantage of unique
sequences (referred to as barcodes below) present in the
hairpin-flanking regions of miRNA-coding genes. Complemen-
tary oligonucleotides to barcode sequences were coupled to
polystyrene beads embedded with unique combinations of fluo-
rophores. Genomic DNA samples from library-transduced cells
could be PCR amplified with biotinylated primers specific to
the expression vector, hybridized to the barcode-detector-
coupled beads, and labeled with streptavidin-phycoerythrin. A
flow cytometer was then used to report the identity of the beads
and quantify the barcode abundance detected on each bead.
This bead-based detection system has the specificity and
reproducibility required for robust barcode quantification of the
miRNA library. To test detection specificity, genomic DNA from
miR-29a-transduced HL-60 cells was assayed, and signal was
only observed from the respective miR-29a detector (Fig-
ure S1D). We next pooled the 135 library constructs, produced
virus, and transduced HL-60 cells. The majority of barcodes
(130 out of 135, or 96%) could be robustly detected above back-
ground (Figure S1D). Independent PCR amplifications from the
same genomic DNA sample produced low variance in signals,
indicating that the detection system is reproducible (Figure S1E).
Thus, with the availability of the expression library and a reliable
barcode detection system, we proceeded to the in vivo screen.
An In Vivo Gain-of-Function Screen Reveals Candidate
miRNAs Involved in Regulating Hematopoietic Recovery
To uncover miRNA-mediated regulation of hematopoietic injury
response upon 5-FU treatment, we performed an in vivo func-
tional screen as illustrated in Figure 1. Adult murine donor
bone marrow cells were transduced with the miRNA expression
library as a pool and transplanted into lethally irradiated recipient
mice. To ensure that donor cells contained largely single copy
integrations of the viral constructs, we titered the miRNA library
to a transduction efficiency of10%–25%. After transplantation,
we harvested peripheral blood of recipients at defined intervals,
both to monitor the level of engraftment and to prepare genomic
DNA for barcode detection. Once engraftment reached relatively
stable levels at 11 weeks posttransplantation (Figures S2A and
S2B), the recipient animals were treated with 5-FU. Day 10
post-5-FU reflected the time point with strong hematopoietic
suppression, whereas day 22 represented normalization of the
blood parameters (Figure S2C). We reasoned that miRNAs with
barcode signals decreased after 5-FU treatment would suggestReports 2, 1048–1060, October 25, 2012 ª2012 The Authors 1049
Figure 1. Schematic of the In Vivo miRNA
Screen
Donor bone marrow cells were transduced with
a pooled miRNA expression library and trans-
planted into lethally irradiated recipient mice.
Peripheral blood samples were collected at indi-
cated weeks (Wk) posttransplantation. Mice were
challenged with 5-FU 3 days after the week 11
collection and sampled at indicated days post-5-
FU. Genomic DNA (gDNA) was isolated from
peripheral blood and subjected to barcode anal-
ysis. See also Figure S1 and Tables S2 and S5.an inhibitory role upon 5-FU-induced hematopoietic recovery,
whereas those that increased would be potential enhancers of
this process.
A key consideration for the screen is the functional heteroge-
neity of HSPCs. Some dominant HSPC clones may have
a stronger contribution to peripheral blood than other clones.
Thus, miRNAs landing in such clones could be misclassified as
enhancers of recovery, even though they do not function in this
capacity. Conversely, miRNAs integrating into weak HSPC
clones could be misclassified as inhibitors. To avoid HSPC
heterogeneity confounding interpretation of barcode results,
we used a short duration of viral transduction to minimize prolif-
eration of HSPCs during ex vivo culture, thus reducing the
likelihood that descendants of the same HSPC clone could be
transplanted into different animals. We also performed three
independent viral transductions and transplanted into a total of
15 mice, further reducing the possibility of dominant HSPC
clones rendering false-positive results in multiple recipients.
Quantification of barcodes revealed several interesting
features from this screen:
(1) Barcode signals could be reliably detected from periph-
eral blood collections of recipient animals, above detec-
tion background (Figures S3A–S3C).
(2) On average, the effect of 52 different miRNAs could be
assayed in each recipient mouse. At 3 weeks posttrans-
plantation, each recipient contained 62–108 detectable
barcodes. This number decreased with time and was
largely stabilized by week 11 posttransplantation to 35–
71 detectable barcodes in each animal (Figure 2A). This
drop in barcode number is likely due to preferential retro-1050 Cell Reports 2, 1048–1060, October 25, 2012 ª2012 The Authorsviral transduction of transiently
amplifying progenitors that only
support short-term contribution to
peripheral blood, whereas contri-
bution from the less-transduced
but more primitive HSPCs sup-
ports longer-term engraftment.
Constitutive expression of miRNAs
that antagonize engraftment may
also contribute to this reduction in
barcode number.
(3) Barcode patterns differ between
mice. Unsupervised clustering of
barcode abundance showed thatafter 3 weeks posttransplantation, there were more differ-
ences in barcode patterns between mice than across
different time points within the same mouse (Figure 2C).
This result suggests that different sets of miRNAs were
transduced in different mice and indicates that barcode
abundance changes should only be compared within
the same recipient across time points.
(4) A large number of barcodes could be collectively de-
tected within the entire screen cohort. At week 3 post-
transplantation, 124 barcodes out of 135 (92%) could
be detected in at least one recipient, and 115 barcodes
(85%) could be detected in at least five different recipients
(Figure S3D). At the time points specifically associated
with the 5-FU assay (week 11 and 10 days post-5FU),
124 barcodes (92%) could be detected in at least in one
mouse, whereas 88 barcodes (65%) were present in at
least five mice (Figure 2B). Taken together, the above-
mentioned data indicate that it is possible to use a small
number of animals to quantify the effects of a moderate
number of genes.
To assess the effect of miRNAs during hematopoietic injury
response to 5-FU administration, we considered the effect of
HSPC heterogeneity and reasoned that miRNA barcodes that
showed consistent changes in multiple animals were more likely
true candidates rather than false positives. To reflect this
concept, we used a consistency score to quantify the barcode
abundance changes in the screen cohort (see Experimental
Procedures). After comparing day 10 and day 22 post-5-FU
time points with the closest pre-5-FU time point (week 11), we
assigned downregulation of barcode signals in each mouse
Figure 2. Barcode Analysis from the In Vivo
Screen
(A) Barcodes were measured from red cell-lysed
peripheral blood samples (effectively from all
nucleated cells). The number of barcodes de-
tected in each mouse at different time points is
shown. Data were grouped by individual mice from
a total of three independent cohorts of 15 mice.
(B) The number of unique barcodes detected in the
screen cohort is shown for week 11 post-
transplantation and day 10 post-5-FU. Data
represent the number of barcodes that can be
detected in at least the specified number of mice.
(C) Unsupervised clustering of barcode intensity
primarily groups samples by recipient mice. A
representative heatmap is shown in which log2-
transformed data from samples collected at indi-
cated weeks posttransplantation and days (D)
post-5-FU were analyzed. Blue indicates lower
signal, whereas red indicates higher signal.
See also Figure S2 and Table S5.as 1 and upregulation as +1. Thus, miRNAs that antagonized
hematopoietic recovery would have a negative consistency
score, whereas miRNAs that enhanced recovery would have
a positive score. Ranking miRNAs based on these scores, we
found that a small number of miRNAs showed consistent trends
(Figure 3A), and the rankings were insensitive to variations in
analysis parameters (Experimental Procedures; Table S3), indi-
cating minimal analysis artifact.
Upon close inspection, upregulated barcodes showed less
consistency, with changes sometimes driven by a single screen
cohort. We thus focused on the top four miRNAs whose barcode
abundance was decreased in the screen and was distributed
across multiple cohorts and across both post-5-FU time
points (Table S3; Figures 3A, 3B, and S3E). Thus, miR-153-2,
miR-150, miR-301, and miR-652 (ranked from top down) were
chosen for further experimental validation.
Forced Expression of miR-150 and Other Candidates
Inhibits Hematopoietic Recovery upon 5-FU Treatment
To validate screen candidates, we transduced miR-153-2, miR-
150, miR-301, miR-652, or a vector control into donor bone
marrow cells and assayed the recovery of these cells in trans-
plant recipients after 5-FU treatment. A constitutive GFP on the
vector labeled transduced cells, so competitive recovery ofCell Reports 2, 1048–1060, Otransduced cells versus nontransduced
cells within the same recipient mouse
could be reflected by GFP+/GFP ratio
changes in the peripheral blood. In addi-
tion, by using lineage-specific antibodies,
we could determine the effects of the
miRNA candidates on Mac1+ (CD11b)
myeloid cells, B220+ (CD45R) B cells,
CD3+ T cells, as well as anuclear CD41+
platelets. For transplant recipients, we
followed the GFP+/GFP ratio after trans-
plantation and waited until the ratio
largely stabilized before treating micewith 5-FU (Figures S4A and S4B; data not shown). In control
recipients, the GFP+/GFP ratio in all examined lineages showed
relatively minor perturbations following 5-FU treatment, likely
due to mild toxicity of GFP expression (Figure 4). In contrast,
the expression of miR-153-2 or miR-150 strongly inhibited both
myeloid and platelet recovery (Figures 4A and 4B). Interestingly,
expression of the weaker candidate miR-652 led to a weaker yet
significant suppression of myeloid and platelet recovery (Fig-
ure 4C). Candidate miR-301 did not cause significant changes
and is thus a false positive (data not shown). In total, we success-
fully validated three out of four candidate miRNAs from the
screen. Because miR-150 caused a strong inhibitory effect in
the validation experiments and is the only miRNA among the
three validated candidates that has an available knockout model
(Xiao et al., 2007), we thus focused on this miRNA for follow-up
experiments.
The miR-150 recipient cohort displayed a significant and
sharp decrease in the GFP+/GFP ratio in both myeloid and
platelet lineages as early as 7 days post-5-FU (Figure 4A). This
strong suppression of the GFP ratio persisted for 2–3 months
and then gradually recovered to levels similar to that of the
control cohort. The strongest ratio differential between miR-
150 and the control cohort was at 16 days, with platelets sup-
pressed by 4.8-fold and myeloid cells by 2.6-fold. B andctober 25, 2012 ª2012 The Authors 1051
Figure 3. In Vivo Screen Identifies Candidate miRNAs that Inhibit Hematopoietic Recovery
(A) A representative heatmap for consistency score evaluation of the screen. Comparisons between Day 10 and 22 post-5-FU time points to week 11 were
calculated for each mouse (data in rows) and each miRNA barcode (data in columns). Not detected (N.D.) barcodes are shown in gray. Increased barcodes
passing a change threshold are indicated in red, with those below the threshold in blue, and those not changed (neutral) in white.
(B) Barcode intensity decreases for miR-150 were compared in individual recipient mice between Day 10 or Day 22 post-5-FU andWeek 11 pre-5-FU time points.
A total of 13mice had a detectable miR-150 barcode signal associated with these time points, with mouse identification (ID) shown at bottom. Day 22 samples for
cohort 2 (mice 6–10) did not pass quality control and are not shown (see Experimental Procedures). Solid red line indicates no change. Dashed red lines indi-
cate +0.6 and 0.6 of log2-fold changes that were used as the ‘‘change threshold’’ in (A). The circle (C) indicates that corresponding bar is not shown to the
full height.
See also Figure S3 and Table S5.T lymphoid lineages were overall constitutively inhibited by
the expression of miR-150 (Xiao et al., 2007; Lu et al., 2008),
reflected by a lower initial GFP+/GFP ratio (Figure S4C). Never-
theless, a ratio drop was also observed post-5-FU (Figure 4A),
albeit to a lesser extent than myeloid and platelet lineages.
Similar to myeloid cells, the GFP+/GFP ratio of lymphoid cells
recovered close to control levels after long duration. The time
course of GFP+/GFP ratio normalization suggests that forced
expression of miR-150 possibly negatively regulates hematopoi-
etic output from multiple bone marrow progenitor populations,
includingmultipotent progenitors, commonmyeloid progenitors,
and lineage-committed progenitors, but with a lesser effect on
long-term stem cells.
miR-150 Knockout Bone Marrow Confers
an Accelerated Recovery Response to
Hematopoietic Injury
We asked whether loss of miR-150 induces an opposite pheno-
type as compared to miR-150 gain of function, i.e., accelerating
hematopoietic recovery. The germline miR-150 knockout mice1052 Cell Reports 2, 1048–1060, October 25, 2012 ª2012 The Authowere viable and normal in fertility, development, and behavior
(Xiao et al., 2007). Further examination of hematopoietic tissues
revealed largely normal steady-state hematopoiesis. Peripheral
myeloid, lymphoid, and red cell counts of miR-150/ mice
were indistinguishable from wild-type littermates (Figures 5A
and S5B). Similarly, proportions of bone marrow and spleen
Ter119+, Mac1+, CD3+, and B220+ cell lineages were similar to
controls (Figure S5C). Although peripheral platelet counts and
spleen megakaryocyte frequency trended lower in the knock-
outs, the differences were not statistically significant (Figures
5A and S5D). Note that although changes in specific B cell
subsets (Figure S5A), NK, and iNKT cells have been reported
in miR-150 knockout mice (Xiao et al., 2007; Bezman et al.,
2011; Zheng et al., 2012), changes in these populations were
not expected to change the overall peripheral blood cell counts.
To investigate hematopoietic injury response, we conducted
competitive recovery experiments, as illustrated in Figure 5B.
We genetically labeled the majority of platelets and nucleated
blood cells by crossing miR-150/ mice with b-actin-GFP
mice (Okabe et al., 1997). Bone marrow cells from GFP+rs
Figure 4. Forced Expression of miR-150 and Other Candidates Impairs Hematopoietic Recovery upon 5-FU Treatment
(A–C) Competitive recovery of transduced cells (GFP+) compared with nontransduced cells (GFP) in mosaic transplantation hosts is shown for Mac1+ myeloid,
B220+ B cell, CD3+ T cell lineages, andCD41+ platelets in the peripheral blood. Green arrow indicates the time point ofmaximal difference among themiR-150 (A),
miR-153-2 (B), miR-652 (C), and control cohorts in platelets, myeloid, B cell, and T cell lineages. GFP+/GFP ratios were normalized to that of day3 before 5-FU
treatment. Error bars represent SD (n = 15 for A, n = 4 for B and C). *p < 0.05.
See also Figure S4.miR-150/ or GFP+ miR-150+/+ mice were mixed 1:1 with GFP
wild-type bone marrow and transplanted into wild-type recipi-
ents. After reestablishment of hematopoietic homeostasis and
GFP+/GFP ratio stabilization (Figure S5E), recipient mice wereCellchallenged with 5-FU. Examination of peripheral blood GFP+/
GFP ratios indicated that miR-150/ myeloid cells and plate-
lets recovered faster than wild-type controls (Figure 5C). Signif-
icant differences of the competitive ratio for platelets betweenReports 2, 1048–1060, October 25, 2012 ª2012 The Authors 1053
Figure 5. miR-150 Null Bone Marrow Confers Faster Peripheral Recovery upon 5-FU Injury
(A) The homeostatic levels of blood parameters are indistinguishable betweenwild-type (WT) andmiR-150 knockout (KO) littermates. Complete blood counts are
shown. WBC, white blood cells; HCT, hematocrit. Error bars indicate SD (n = 12).
(B) A schematic depicting competitive recovery assays comparing wild-type or miR-150 knockout cells with wild-type competitor bone marrow. Transplant
recipients were tested for 5-FU injury response after donor bone marrow cells repopulated the recipient hematopoietic system and reached homeostasis. GFP
was used to trace miR-150 knockout cells or those from wild-type littermates. CD45.1 and CD45.2-based tracing was used in a parallel experiment (see also
Figure S5G). eGFP, enhanced green fluorescent protein.
(C) Competitive recovery of GFP+ miR-150 knockout cells or that of wild-type controls was compared with wild-type competitors (GFP) and measured
by peripheral GFP+/GFP ratios. Data were from two independent cohorts and normalized to the ratios 3 days before 5-FU treatment. Error bars represent SD
(n = 12). Green arrow indicates the time point with maximal difference between WT and KO cohorts for myeloid cells. *p < 0.05.
See also Figure S5.
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knockout and control cohorts were observed from day 12, with
the maximum increase of 34.5% at 22 days post-5-FU. For
myeloid cells, a maximal ratio increase of 50.1% was also
observed at day 22. B and T lymphocytes showed only minor
ratio alterations, similar to the aforementioned forced expression
model.
Unexpectedly, the GFP+/GFP ratios of myeloid and lymphoid
cells (but not platelets) showed a time-dependent fluctuation,
even in the wild-type control cohort, which may be partially
due to incomplete GFP labeling of hematopoietic cells in
b-actin-GFP mice (69% GFP+ in peripheral Mac1+ cells;
72% in B220+ cells; 75% in CD3+ cells; 81% in platelets).
To eliminate the possibility that the differences we observed
were due to artifacts of GFP+/GFP ratio fluctuation, we per-
formed competitive recovery experiments using different iso-
forms of CD45. Similar to the GFP model, bone marrow from
CD45.1+ littermates of miR-150/ or miR-150+/+ mice was
mixed 1:1 with CD45.2+ wild-type bone marrow cells and trans-
planted into lethally irradiated CD45.2+ recipients (Figure 5B).
5-FU was administered following recovery from transplantation
and CD45.1+/CD45.2+ ratio stabilization (Figure S5F). Consistent
with the GFPmodel, the myeloid lineage showed faster recovery
in the knockout cohort, whereas B and T lymphocytes were
largely similar to controls (Figure S5G). Because CD45 is not ex-
pressed on platelets, platelet ratios could not be assessed.
Taken together, the aforementioned experiments established
that loss of miR-150 accelerated the recovery of myeloid and
platelet lineages after injury.
Expression of miR-150 Impairs Bone Marrow
Clonogenic Potential upon 5-FU Treatment
To further elucidate how miR-150 inhibits hematopoietic
recovery, we reasoned that forced expression of miR-150 could
impair the function of multiple bone marrow progenitors upon
5-FU administration. This hypothesis is consistent with our
observation in Figure 4A, in which the ratio of miR-150-trans-
duced to -nontransduced cells in the peripheral blood was
sharply decreased for several weeks and then gradually recov-
ered after an extended period of time. To test this, we generated
bone marrow transplant recipients expressing miR-150 or
the vector control. After peripheral GFP+/GFP ratios stabilized,
we isolated GFP+ (transduced) and GFP (nontransduced) bone
marrow populations from the same recipient mouse and tested
their clonogenic potential in vitro. The GFP+ and GFP cells
from both miR-150 and control vector recipients gave rise to
similar frequencies of myeloid colonies (Figure 6A), indicating
that expression of miR-150 did not adversely affect colony
formation under homeostatic conditions. In contrast, for bone
marrow cells harvested 6 days after 5-FU administration, GFP+
cells from miR-150 recipients showed an 2.9-fold decrease in
myeloid clonogenic potential, whereas GFP cells from the
same recipient produced similar frequencies of colonies
compared to control vector recipients (Figure 6A). Pre-B cell
colonies were less severely affected by miR-150 (Table S4).
Upon closer examination, this decrease in myeloid colony
formation of miR-150-expressing cells impacted all types of
colonies, including erythroid, granulocytic/monocytic, and
the more primitive GEMM colonies (Table S4), supporting theCellnotion that multiple types of hematopoietic progenitors were
compromised.
We then examined the miR-150 knockout model. Under
steady-state hematopoiesis, no difference in myeloid colony
number was observed between knockout and wild-type mice.
In contrast, when we examined bone marrow after 5-FU treat-
ment, miR-150 knockout cells generated a significant increase
in the number of myeloid colonies compared to controls (Fig-
ure 6B; Table S4). These data indicate that miR-150 inhibits
bone marrow colony formation upon 5-FU-induced injury.
This colony inhibition effect could be due to miR-150 inhibiting
hematopoietic progenitor function during stressed hematopoi-
esis or sensitizing progenitors to 5-FU-induced cell death, or
both. We tested the first possibility using a postirradiation hema-
topoietic recovery model. Wild-type bone marrow cells were
transduced with miR-150 or vector control, sorted for GFP+-
transduced cells, and transplanted into irradiated recipients.
Ten days after transplantation, miR-150 expression resulted in
significantly reduced spleen colony formation (Figure 6C), which
is an in vivomeasure of hematopoietic progenitor activity (Till and
McCulloch, 1961). Importantly, because only the transplant
hosts were irradiated but not the donor cells, this experiment
measured postinjury responses rather than injury itself. Thus,
we conclude that miR-150 can inhibit hematopoietic progenitor
function during states of stress or injury.
To investigate whether miR-150 sensitizes bone marrow cells
to 5-FU-mediated apoptosis, we first transduced wild-type
HSPCs (LinSca+ Kit+) with mir-150 or control vector. Cultured
HSPCs were then treated with 5-FU in vitro and monitored for
apoptosis by flow analysis of the AnnexinV+7AAD population
in transduced (GFP+) and untransduced (GFP) fractions.
Compared to controls, miR-150-transduced cells showed higher
basal apoptosis, which was further elevated upon 5-FU treat-
ment (Figures 6D and S6A), indicating that miR-150 can sensitize
HSPCs to apoptosis in vitro. However, we did not observe
changes in apoptosis in vivo using the miR-150 overexpression
model described above (Figures 6E and S6B), at 6 days post-
5-FU when apoptosis was prevalent (data not shown). These
data suggest that the inhibitory effect of miR-150 on bone
marrow progenitors may also be due to enhanced apoptotic
sensitivity toward injury. Taken together, the data above show
that forced expression of miR-150 suppressed the bone marrow
clonogenic potential after 5-FU administration.
Heterozygous Loss of the miR-150 Target c-myb
Partially Phenocopies miR-150 Overexpression
To understand the molecular mechanism by which miR-150
inhibits hematopoietic recovery, we focused on the conserved
miR-150 target c-myb (Xiao et al., 2007; Lu et al., 2008; Barroga
et al., 2008). We asked whether heterozygous loss of c-myb
could phenocopy miR-150 overexpression, i.e., having a hema-
topoietic-autonomous effect to suppress hematopoietic output
in response to 5-FU-induced injury. We examined a conditional
heterozygous c-myb model because germline knockout of
c-myb is embryonic lethal (Mucenski et al., 1991), and condi-
tional homozygous knockout of c-myb in the hematopoietic
system quickly depletes hematopoietic stem cells (Lieu and
Reddy, 2009). In addition, because miRNAs do not completelyReports 2, 1048–1060, October 25, 2012 ª2012 The Authors 1055
Figure 6. Forced Expression of miR-150 Inhibits Hematopoietic Progenitor Activity upon 5-FU-Induced or Irradiation Injury
(A) Bone marrow cells transduced with miR-150 or a control vector (GFP+), and those not transduced (GFP), were sorted from transplant recipients and were
subjected to colony formation assays. Both mice without 5-FU treatment and 6 days post-5-FU were analyzed. Results were from three pairs of miR-150 and
control recipients. *p < 0.05.
(B) Bone marrow clonogenic potential from wild-type and miR-150 knockout mice was similarly assayed with or without 5-FU treatment (n = 4). *p < 0.05.
(C) Spleen colony formation potential in miR-150 or control transplant recipients. Wild-type bone marrow was transduced with miR-150 or control vector. GFP+
cells were sorted, and 1.5 3 104 cells were injected into irradiated recipients. Ten days post transplantation, the number of spleen nodules was counted, and
spleen weight was also determined. Images are representative of spleen morphology for each cohort (n = 4). *p < 0.05. All figure error bars depict the SD.
(D) LinKit+Sca+ HSPCs were transduced with miR-150 or a control vector, treated in vitro with or without 5-FU, and assayed at indicated days. AnnexinV+ cells
were analyzed after gating on 7AAD population for both transduced (GFP+) and untransduced (GFP) cells in the same culture. Error bars represent SD (n = 3).
*p < 0.05.
(E) Bonemarrow cells frommiR-150 or control vector recipients were analyzed for apoptosis by examining the AnnexinV+ 7AAD population in both Lin and Lin+
populations, 6 days after 5-FU treatment in vivo. Error bars represent SD (n = 3).
See also Figure S6 and Table S4.
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Figure 7. Heterozygous Loss of c-myb Partially Phenocopies miR-150-Forced Expression
(A) Schematic of competitive recovery of c-myb heterozygous knockout cells. CD45.1/.2+ MybF/+Mx1Cre+ bone marrow cells or MybF/+Mx1Cre cells were
cotransplanted with CD45.2+ wild-type cells. After mice recovered from pIpC-induced deletion of c-myb, mice were challenged with 5-FU, and competitive
recovery was measured in peripheral blood.
(B) The ratios of the test cells (CD45.1/.2) to competitor cells (CD45.2) were measured in peripheral blood before and after 5-FU treatment. The 45.1/45.2 ratios
were normalized to the day 3 time point. Error bars represent SD (n = 4). *p < 0.05.
See also Figure S7.suppress the expression of their target gene(s), heterozygous
loss of the target better mimics miRNA action.
Competitive recovery experiments were performed to assay
the role of c-myb (Figure 7A). CD45.1+/CD45.2+ bone marrow
cells from Mx1-Cre+;Mybfl/+ mice or Mx1-Cre;Mybfl/+ mice
were mixed 1:1 with CD45.2+ wild-type bone marrow cells and
transplanted into CD45.2+ recipients. All recipient mice, regard-
less of the status of the Mx1-Cre allele, were injected with pIpC,
a standard treatment to induceMx1-Cre expression in the hema-
topoietic system. After the excision of c-myb was confirmed in
the Cre+;Mybfl/+ recipients (Figure S7A) and blood parameters
stabilized (Figures S7B and S7C), recipient mice were treated
with 5-FU, and the ratio between CD45.1+ cells and competitor
CD45.2+ cells was quantified. Note that we waited 35 days
between the pIpC and 5-FU treatments to avoid an effect on
stem cell activation (Essers et al., 2009). As expected, nonexcis-
able Mx1-Cre;Mybfl/+ cells behaved similarly to wild-type
competitor cells. In contrast, Mx1-Cre+;Mybfl/+ cells showed
slower recovery in the myeloid lineage, but not in lymphoid line-
ages (Figure 7B). We also crossed the Mx1-Cre+;Mybfl/+ mice
with b-actin-GFP mice to examine platelets. Indeed, heterozy-
gous loss of c-myb also decreased the platelet recovery rate
(Figure S7E), although the level of inhibition on myeloid and
platelet lineages was less compared to miR-150 overexpressionCell(Figure 4A). Also similar to the miR-150 overexpression model,
myeloid clonogenesis trended lower after 5-FU treatment in
heterozygous c-myb knockout cells (Figure S7D; Table S4).
Overall, these data demonstrate that heterozygous loss of
c-myb partially recapitulated the phenotypes associated with
the miR-150 gain-of-function model.
DISCUSSION
This study demonstrates the feasibility to perform in vivo miRNA
screens in live mice with a barcoded library and the power to
uncover regulators of complex physiological processes. The
finding through the screen that miR-150 impaired hematopoietic
injury response contrasts the miRNA expression-profiling results
comparing bone marrow samples with or without 5-FU treat-
ment, which found 92 out of 168 (55%) miRNAs with significant
expression changes (Figure S1A). Interestingly, miR-150 was
among the 45% of miRNAs that were not significantly changed
after 5-FU treatment (Table S1). These results reiterate usual
problems associated with gene-profiling studies: that the result-
ing miRNA changes are often too numerous to study. On the
other hand, functionally important genes may be missed with
profiling. Even after we identified miR-150, measuring miR-150
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populations did not yield intuitive expression patterns associ-
ated with its functional importance: miR-150 expression was
higher and c-myb lower in post-5-FU samples than thosewithout
treatment (Figure S6C). Similarly, the complex nature of our
measured hematopoietic injury response, which reflects the clin-
ically relevant rebound of circulating mature cells within the
peripheral blood after acute injury, can be challenging to model
in vitro. We performed two experiments to measure the effect
of forced miR-150 expression in cultured Ficoll-purified bone
marrow cells but did not observe any differential competitive
expansion/survival disadvantage in the presence of varying
amounts of 5-FU (data not shown). We only detected changes
in apoptosis when starting with purified HSPCs, suggesting
that it would have been difficult to discover the role of miR-150
in hematopoietic injury response in a culture dish without the
initial in vivo screen.
The bead-based detection system for genetic barcodes is
specific and reproducible for functional screens. Compared to
next-generation sequencing, it is inexpensive, flexible to design,
and more readily accessible. The inexpensiveness makes it
more attractive to run small sample batches, such as those
during assay set up, or screens with a medium-sized library. It
is likely less sensitive compared to next-generation sequencing
and less powerful for large genetic libraries, but our detection
rate in mouse (92% of the library at 3 weeks) suggests that suffi-
cient sensitivity of detection can be achieved for libraries of
100–200 genes in complexity.
The data presented in this study highlight the role of miR-150
in controlling hematopoietic recovery after injury. Although the
functional screen was designed to uncover regulatory miRNAs
that control short-term peripheral blood recovery after acute
injury, which is highly relevant to clinical management of patients
receiving chemotherapy, the effects with miR-150 overexpres-
sion and knockout studies could be seen within the short-term
window of 1–3 weeks and also beyond. The miR-150 overex-
pression model showed weak but significant lymphoid recovery
changes, which was not seen in the miR-150 knockout model.
This difference may be due to forcing miR-150 expression in
cell types that normally do not express miR-150. Our finding,
that miR-150 suppresses multiple types of hematopoietic
progenitor activities, including both immature and more mature
myeloid progenitors upon 5-FU treatment, provides one expla-
nation for the observed short-term and longer-term effects of
miR-150. It is important to note that this progenitor cell effect
of miR-150 does not contradict previous knowledge of miR-
150 in specific lineage differentiation (Lu et al., 2008; Barroga
et al., 2008; Xiao et al., 2007; Bezman et al., 2011; Zheng
et al., 2012). For example, even though the forced expression
of miR-150 elevates platelet production in comparison to
myeloid cells (Figure S4C) under homeostatic conditions as ex-
pected, upon hematopoietic recovery from acute injury, miR-
150 affected more upstream progenitors that largely masked
this platelet production bias.
Mechanistically, we show that hematopoietic-intrinsic hetero-
zygous loss of c-myb produced similarly delayed recovery after
5-FU. It is known that c-myb regulates proliferation and
apoptosis-related genes, such as c-myc, cyclins, KIT, Bcl-2,
and Bcl-XL (Ramsay et al., 2003; Ramsay and Gonda, 2008),1058 Cell Reports 2, 1048–1060, October 25, 2012 ª2012 The Authosome of which may mediate c-myb’s function in hematopoietic
recovery. The delayed recovery in the c-myb model was
both shorter and weaker than the gain of function of miR-150
and did not affect the lymphoid lineages. We speculate that
additional targets may also be involved, or the difference in
phenotype may be due to quantitative differences in c-myb
suppression in the two models.
It is intriguing that loss of miR-150 had mild effects on steady-
state hematopoiesis (other than B cell subsets, NK and iNKT
cells), yet knockout cells displayed the beneficial effect of accel-
erated rate of hematopoietic recovery in the peripheral blood.
This is somewhat puzzling given that miR-150 is evolutionarily
conserved from human to frog, although it is possible that the
roles of miR-150 in specialized immune cell production, or anti-
cancer effect in lymphoma (Chang et al., 2008), contribute to
the pressure for genetic conservation. Nevertheless, our data
suggest that an interesting avenue to explore in the future will
be to temporarily suppress miR-150 activity for the clinically
beneficial outcomes of faster platelet and myeloid cell recovery.
Because mice null of miR-150 show largely normal behaviors, it
suggests that inhibition ofmiR-150may have limited side effects.
The recent progress in in vivo delivery of miRNA inhibitors (Sten-
vang et al., 2012) will, in the future, help to test this concept in
a more translational setting.
EXPERIMENTAL PROCEDURES
Mouse Strains and Maintenance
All mouse studies were conducted in accordance with federal guidelines and
were approved by the Institutional Animal Care and Use Committee of Yale
University. See Extended Experimental Procedures for more details.
Constructing a miRNA Expression Library
Design of the retroviral expression library was carried out based on sequence
information present in miRBASE v9.0 (Kozomara and Griffiths-Jones, 2011).
Desired miRNA hairpins for the library were identified in the human genome,
and their200 bp flanking sequences were scanned for the presence of other
miRNAs or polyA signals. Specific primers (see Table S1) were designed so
that they can uniquely amplify the corresponding miRNA, and through
a two-step approach, cloned into the pMIRWAY-GFP vector (Guo et al.,
2010; Lu et al., 2008). Retrovirus was produced in 293T cells from a pooled
plasmid preparation of the pMIRWAY-miRNA library. See Extended Experi-
mental Procedures for more details.
In Vivo miRNA Screen and Barcode Detection
For the in vivo screen, donor adult bone marrow cells were transduced with
pooled miRNA viral library, and murine bone marrow transplantation was per-
formed similar to published procedures (Guo et al., 2010). Starting from
3 weeks posttransplantation, genomic DNA isolates from the peripheral blood
samples were prepared for barcode detection by first performing PCR to
amplify the miRNA cassette. PCR products were purified using a QIAquick
PCR Purification Kit (QIAGEN), and miRNA barcodes were detected using
a Luminex bead-based detection system. Acquired median fluorescence
intensity values were then used in subsequent data analysis. See Extended
Experimental Procedures for more details on transplantation, sample prepara-
tion, barcode detection, and signal analysis.
Murine Bone Marrow Transplantation
For singlemiRNAoverexpression studies,murine bonemarrow transplantation
was performed similar to published procedures (Guo et al., 2010). For the miR-
150 and c-myb competitive transplant assays, bone marrow was collected
from donor animals, mixed at a 1:1 mononuclear cell ratio with CD45.2 wild-
type competitor cells, and injected into 9.0 Gy irradiated recipient mice.rs
For determining theGFP ratios of different peripheral blood lineages, periph-
eral blood was lysed and stained with the following antibody mixture: Mac-1-
PE, B220-APC, and CD3-PE-Cy5 in PBS +2% FBS. For experiments using the
45.1 congenic system, CD45.1-FITC was added to the antibody mixture. To
assess GFP ratios in platelets, peripheral blood was stained with CD41-PE
in sodium citrate buffer, fixed in 1% PFA, and analyzed on FACSCalibur.
See Extended Experimental Procedures for details.
Statistical Analysis
Student’s t test was used for p value calculation unless specified otherwise.
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The GEO accession number for the miRNA profiling data is GSE39211.
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